Regeneron, Sanofi to Co-Develop Four New Long-Acting Antibodies
Regeneron to receive USD 1 billion upfront payment from Sanofi, with potential for up to an additional USD 7 billion in future milestone payments.
Regeneron to receive USD 1 billion upfront payment from Sanofi, with potential for up to an additional USD 7 billion in future milestone payments.
MenQuadfi was previously approved in the European Union for individuals aged 12 months and older against invasive meningococcal disease.
The EU has cleared Sanofi’s Cenrifki (tolebrutinib) as the first therapy to target disability progression in secondary progressive multiple sclerosis without relapses, while Japan has approved Wayrilz for immune thrombocytopenia (ITP).
Abu Dhabi DoH and Sanofi have strengthened their partnership to advance vaccine innovation and to jointly explore the development of a Vaccine Innovation Centre in Abu Dhabi.